阿片类镇痛药治疗急性下背痛和颈痛(OPAL试验):随机安慰剂对照试验
OPAL是一项三盲、安慰剂对照随机试验,在澳大利亚悉尼157个初级保健或急诊站点招募347例成人急性(≤12周)下背痛和/或颈痛、疼痛至少中度严重的患者,随机接受指南推荐治疗加羟考酮-纳洛酮(口服羟考酮每日最多20 mg)或加安慰剂,最长6周。主要终点6周疼痛严重程度(简明疼痛量表疼痛严重程度亚量表,10分制)在阿片组为2.78(SE 0.20),安慰剂组为2.25(SE 0.19),调整后平均差0.53(95%CI -0.00至1.07,p=0.051),无统计学显著差异。阿片组至少1项不良事件61/174(35%)vs 安慰剂组51/172(30%)(p=0.30),但阿片相关不良事件更多(如便秘13/174[7.5%] vs 6/173[3.5%])。作者结论认为不应推荐阿片类药物用于急性非特异性下背痛或颈痛。
要点
- 急性非特异性下背痛或颈痛(≤12周、至少中度严重)成人中,指南推荐治疗加羟考酮-纳洛酮(口服羟考酮每日最多20 mg,最长6周)6周疼痛评分2.78 vs 安慰剂2.25,调整后平均差0.53(95%CI -0.00至1.07,p=0.051),无显著差异。
- 阿片组至少1项不良事件35%(61/174)vs 安慰剂组30%(51/172),p=0.30;阿片相关不良事件更多,如便秘7.5%(13/174)vs 3.5%(6/173)。
- 作者结论:不应推荐阿片类药物用于急性非特异性下背痛或颈痛,该发现呼吁改变此类情况中阿片类药物的频繁使用。
- 主要分析纳入阿片组151例、安慰剂组159例;6周时阿片组33/174(19%)、安慰剂组25/172(15%)退出试验。
适用人群与场景
- 成人(年龄≥18岁),因下背痛或颈痛(或两者兼有)且疼痛至少中度严重、病程12周或以内,就诊于澳大利亚新南威尔士州悉尼的157个初级保健或急诊站点之一。
诊断标准与关键阈值
- 急性下背痛或颈痛定义为病程12周或以内,疼痛严重程度至少为中度。
- 主要终点疼痛严重程度采用简明疼痛量表疼痛严重程度亚量表(10分制)在6周时评估。
处置流程与药物剂量
- 指南推荐治疗加阿片类药物:羟考酮-纳洛酮,口服羟考酮每日最多20 mg,最长6周。
- 对照:指南推荐治疗加相同外观的安慰剂,最长6周。
研究设计与关键结果
- OPAL为三盲、安慰剂对照随机试验,2016年2月29日至2022年3月10日招募347例参与者(阿片组174例,安慰剂组173例);170/346(49%)为女性,176/346(51%)为男性。
- 6周时阿片组33/174(19%)、安慰剂组25/172(15%)退出试验,原因包括失访和参与者退出。
- 主要分析纳入阿片组151例、安慰剂组159例;6周平均疼痛评分阿片组2.78(SE 0.20)vs 安慰剂组2.25(SE 0.19),调整后平均差0.53(95%CI -0.00至1.07,p=0.051)。
- 阿片组61/174(35%)报告至少1项不良事件 vs 安慰剂组51/172(30%)(p=0.30);阿片组报告更多阿片相关不良事件,如便秘13/174(7.5%)vs 6/173(3.5%)。
证据类型、等级与局限
- 证据类型:三盲、安慰剂对照随机试验(OPAL试验),在澳大利亚新西兰临床试验注册中心注册(ACTRN12615000775516)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,鉴于与安慰剂相比疼痛严重程度无显著差异,不应推荐阿片类药物用于急性非特异性下背痛或颈痛;该发现呼吁改变此类情况中阿片类药物的频繁使用。
指南或共识出处
- OPAL试验,发表于Lancet;由National Health and Medical Research Council、University of Sydney Faculty of Medicine and Health和SafeWork SA资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Opioid analgesics are commonly used for acute low back pain and neck pain, but supporting efficacy data are scarce. We aimed to investigate the efficacy and safety of a judicious short course of an opioid analgesic for acute low back pain and neck pain.
METHODS: OPAL was a triple-blinded, placebo-controlled randomised trial that recruited adults (aged ≥18 years) presenting to one of 157 primary care or emergency department sites in Sydney, NSW, Australia, with 12 weeks or less of low back or neck pain (or both) of at least moderate pain severity. Participants were randomly assigned (1:1) using statistician-generated randomly permuted blocks to guideline-recommended care plus an opioid (oxycodone-naloxone, up to 20 mg oxycodone per day orally) or guideline-recommended care and an identical placebo, for up to 6 weeks. The primary outcome was pain severity at 6 weeks measured with the pain severity subscale of the Brief Pain Inventory (10-point scale), analysed in all eligible participants who provided at least one post-randomisation pain score, by use of a repeated measures linear mixed model. Safety was analysed in all randomly assigned eligible participants. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12615000775516).
FINDINGS: Between Feb 29, 2016, and March 10, 2022, 347 participants were recruited (174 to the opioid group and 173 to the placebo group). 170 (49%) of 346 participants were female and 176 (51%) were male. 33 (19%) of 174 participants in the opioid group and 25 (15%) of 172 in the placebo group had discontinued from the trial by week 6, due to loss to follow-up and participant withdrawals. 151 participants in the opioid group and 159 in the placebo group were included in the primary analysis. Mean pain score at 6 weeks was 2·78 (SE 0·20) in the opioid group versus 2·25 (0·19) in the placebo group (adjusted mean difference 0·53, 95% CI -0·00 to 1·07, p=0·051). 61 (35%) of 174 participants in the opioid group reported at least one adverse event versus 51 (30%) of 172 in the placebo group (p=0·30), but more people in the opioid group reported opioid-related adverse events (eg, 13 [7·5%] of 174 participants in the opioid group reported constipation vs six [3·5%] of 173 in the placebo group).
INTERPRETATION: Opioids should not be recommended for acute non-specific low back pain or neck pain given that we found no significant difference in pain severity compared with placebo. This finding calls for a change in the frequent use of opioids for these conditions.
FUNDING: National Health and Medical Research Council, University of Sydney Faculty of Medicine and Health, and SafeWork SA.
参考来源
- Jones CMP, Day RO, Koes BW, et al. Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Lancet. 2023. PMID: 37392748. doi:10.1016/S0140-6736(23)00404-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。